Product Details

Trileptal

Oxcarbazepine
60 mg/mL
Oral Suspension

DIN/PIN/NPN

02244673

Manufacturer

Novartis Pharma Canada Inc.

Formulary Listing Date

0000-00-00

Unit Price

Amount MOH Pays

Coverage Status

Exceptional Access Program Product

ODB Formulary Therapeutic Classification

28:12:00 Anticonvulsants

Therapeutic Note

NO

ATC Code

N03AF02

Interchangeable Products

NO

LU Clinical Criteria

NO

EAP Criteria

Therapeutic Class	Reimbursement Criteria
Anticonvulsants	Oxcarbazepine Brand(s): Trileptal Dosage Form/Strength: 150 mg, 300 mg, and 600 mg tablet 60 mg/mL For the treatment of partial seizures in adults and in children aged 6 years and older who have had an inadequate response or intolerance* to at least 3 other formulary agents (prior or current use) including carbamazepine. Intolerance must be described in detail. Warning:* Life-threatening dermatological reactions, including Stevens Johnson Syndrome and toxic epidermal necrolysis, and multi-organ hypersensitivity reactions have been associated with the use of oxcarbazepine. More information may be found on the Health Canada webpage: http://www.hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/prof/trileptal_hpc-cps_e.html Duration of Approval: Lifetime EAP Drug Request Form: Standard Form for EAP Drug Requests

Product Monograph